Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Substituting Lantus®(Insulin Glargine[rDNAorigin]Inj) for a Thiazolidinedione vs. a 3rd Oral Agent as add-on Therapy in Patients Failing a Thiazolidinedione & Sulfonylurea or Metformin Combination

NCT00046462 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00046462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00046462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Substituting Lantus®(Insulin Glargine[rDNAorigin]Inj) for a Thiazolidinedione vs. a 3rd Oral Agent as add-on Therapy in Patients Failing a Thiazolidinedione & Sulfonylurea or Metformin Combination
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2001
Completion date
December 31, 2004
Enrollment
240
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus